- Advertisement -
- July 11, 2025: Glenmark Share Price – Ichnos Glenmark Innovation (IGI), Glenmark’s innovation arm, and the U.S. pharmaceutical giant AbbVie signed an exclusive global licensing agreement on July 10, 2025 for the latter’s ISB 2001, an investigational cancer therapeutic that is presently in Phase I for multiple myeloma. The deal includes an upfront payment of \$700 million, with milestone-based revenue of up to \$1.225 billion depending on regulatory and development success. The rights to develop, produce, and market the medication in North America, Europe, Japan, and Greater China are acquired by AbbVie .
Stock Sentiment & Market Focus
- On July 11, 2025, Glenmark shares were one of the most talked-about investments in the market because of the licensing news and continued observation of its Q1 results. Given these developments, the company is being closely monitored by analysts and investors.
Previous Achievements & Updates on the Drug Pipeline
- In May 2025, ISB 2001 received Fast Track designation from the FDA, which improved its regulatory pathway and accelerated review potential. Glenmark’s stock increased by almost 1.8% as a result of the announcement .
- Glenmark completed the dose‑escalation phase of the Phase I clinical trial, reporting promising early responses and safety data. Full results are expected from the extension study at the 2025 ASCO meeting, on June 2.
- In June–July 2025, Glenmark launched Tevimbra, a lung cancer therapy co-developed with BeiGene (now BeOne Medicines), in India. Since late June, the stock has surged nearly 37%, buoyed by investor optimism toward its entry into immuno-oncology in India.
Summary Snapshot
| Topic | Key Details |
|---|---|
| Licensing Deal | \$700M upfront + up to \$1.225B milestones with AbbVie for ISB 2001 |
| FDA Fast Track Status | Granted for ISB 2001 in May 2025 |
| Trial Progress | Phase I dose-escalation complete; ASCO results expected early June |
| New Market Entry | Launch of Tevimbra in India for lung cancer treatment |
| Stock Impact | ~37% rally since late June; high investor interest in July |
| Outlook | Positive momentum driven by innovation pipeline and global deals |
Implications & Strategy Insights
- Validation of innovation path: The AbbVie collaboration significantly validates Glenmark’s focus on oncology biologics and multispecific therapies.
- Accelerated market access: Fast Track designation and licensing aid faster progression toward regulatory approval and revenue realization.
- Oncology drive: The Indian launch of Tevimbra marks Glenmark’s tangible entry into immune-oncology, a meaningful strategic pivot.
- Investor enthusiasm: Market response indicates strong confidence in Glenmark’s innovation-centric transition and long-term growth potential.
FAQ
Which is better, Glenmark or Cipla?
Glenmark:
- High growth potential: Stock is up ~38% in 3 months, driven by a strong pipeline and a major $700M licensing deal with AbbVie.
- Oncology & Innovation focus: Expanding into high-value therapies like multiple myeloma and immuno-oncology.
- Momentum-driven returns: Outperformed peers recently, including Cipla.
But beware: Higher valuation, recent earnings volatility, and some regulatory risk.
Cipla:
- Stability and consistency: Large, established pharma player with steady earnings and a diverse product mix.
- Lower risk profile: Moderate valuation (P/E ~23 vs. Glenmark’s ~43), consistent dividends (₹13/share).
- Reliable long-term compounder: Slower growth, but dependable.
Verdict:
- Aggressive investors / growth seekers → Glenmark
- Conservative investors / stability-focused → Cipla
Who is the richest pharma?
- Advertisement -
As of mid-2025, the richest pharmaceutical companies—by market capitalization and revenue—are predominantly U.S.-based, with a strong presence of consumer-oriented healthcare players:
Global Leaders
- Eli Lilly – Currently the world’s most valuable drugmaker with a market cap of around $842 billion and leading the obesity and diabetes drug markets.
- Johnson & Johnson – With a market cap near $394 billion, it’s a top-ranked diversified healthcare giant .
- AbbVie – Approximately $261–290 billion market cap, powered by its immunology and oncology portfolio .
- Novo Nordisk, Roche, Merck, Pfizer, and AstraZeneca also rank among the top 10 globally.
🇮🇳 In India
- As of June 2025, Sun Pharmaceutical is India’s most valuable pharma company with a market cap of approximately ₹3.4 lakh crore, followed by Divi’s Labs (
₹1.72 lakh crore) and Cipla (₹1.19 lakh crore). - Glenmark Pharma ranks lower, outside the top 3, in Indian pharma market caps .
Verdict
- Globally: Eli Lilly holds the top reputation as the richest pharma company, driven by blockbuster obesity and diabetes drugs.
- In India: Sun Pharma leads in market value, making it the richest domestic pharma company, not Glenmark or Cipla.
- Between Glenmark and Cipla: Neither is near the top globally, but among Indian peers, Cipla (~₹1.19 lakh crore) is currently more valuable than Glenmark.
What is the new name for Glenmark?
The former Glenmark Life Sciences has officially rebranded and is now known as Alivus Life Sciences Ltd., effective January 20, 2025. This follows the acquisition of a 75% stake by Nirma Limited, a diversified conglomerate. The rebranding reflects a strategic shift and renewed focus under its new ownership